← Back to all trials
Recruiting
NCT05635110
Evaluation of the Effects of Omeprazole and Rifampin on the Pharmacokinetics of VX-548 in Healthy Participants
Conditions: Pain
Sex: All
Ages: 18 Years – 55 Years
Healthy volunteers: 1
Phase: PHASE1
Enrollment: 30
Sponsor: Vertex Pharmaceuticals Incorporated
Location: Australia
Summary
The purpose of this study is to evaluate the pharmacokinetics and safety of VX-548 and its metabolite in the absence and presence of omeprazole or rifampin, in healthy participants.
Eligibility Criteria
Key Inclusion Criteria:Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m^2)A total body weight greater than (>) 50 kgKey Exclusion Criteria:History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drugAny condition possibly affecting drug absorptionHistory of cardiovascular diseaseParticipants of child-bearing potentialOther protocol defined Inclusion/Exclusion criteria may apply.
Source: ClinicalTrials.gov (NCT05635110). StuddyBuddy aggregates publicly available trial information.
